Skip to content
Toggle main navigation
EndoForum logo
EndoForum logo
  • Join Today
    Log in
    Select an available language
    EN

    Endocrine News

    Endocrine News provides an in-depth look at trends in the field of endocrinology as well as a closer look at recently published research.

    Filter by category
    All
    Adrenal
    Advocacy
    Bone and Mineral
    Cardiometabolic
    Clinical
    COVID-19
    Diabetes
    Diabetes News and Research
    Diabetes Research Articles
    Early Career Corner
    See all

    Results (34)

    Pharma Friday – November 21, 2026

    Pharma Friday – November 21, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia On November 14, Amylyx Pharmaceuticals, Inc. presented the results from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial of avexitide, an invest
    November 20, 2026
    Pharma Friday – November 13, 2026

    Pharma Friday – November 13, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences On Nov. 9, Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical n
    November 13, 2026
    Pharma Friday – October 30, 2026

    Pharma Friday – October 30, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Glooko Presents Data on Glucose Management Tool’s Effectiveness During Labor and Delivery On October 28, Glooko, Inc., a global digital health company focused on glycemic safety and diabetes management across care settings, announced real-world data presented at the Diabetes Technology Society […
    October 30, 2026
    Pharma Friday – October 23, 2026

    Pharma Friday – October 23, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome Neurocrine Biosciences, Inc. announced on Oct. 22 a publication of expert perspectives highlighting hyperphagia in Prader-Willi syndrome (PWS) as a com
    October 23, 2026
    Pharma Friday – October 16, 2026

    Pharma Friday – October 16, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children On October 16, Ascendis Pharma A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a […]The post Pha
    October 16, 2026
    Pharma Friday – Oct. 2, 2026

    Pharma Friday – Oct. 2, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves First Treatment for MCT8 Deficiency On Sept. 28, the U.S. Food and Drug Administration (FDA) approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid […]The post Pharm
    October 2, 2026
    Pharma Friday – September 18, 2026

    Pharma Friday – September 18, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes KERENDIA® (finerenone), a non-steroidal mineralocorticoid receptor antagonist (MRA), is the first new treatment in more than 30 years […]The
    September 18, 2026
    Pharma Friday – Sept. 11, 2026

    Pharma Friday – Sept. 11, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases On Sept. 8, Moonwalk Biosciences, a biotechnology company developing adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic
    September 11, 2026
    Pharma Friday – September 4, 2026

    Pharma Friday – September 4, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer On August 26, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients […]The post Pharma
    September 4, 2026
    Pharma Friday –  August 14, 2026

    Pharma Friday – August 14, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * From Ascendis: COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. On August 6, Ascendis Pharma A/S provided updates across its achondroplasia programs. “The rapid uptake of YUVIWEL in the United States underscores its highly differentiated […]The
    August 14, 2026
    Pharma Friday – July 17, 2026

    Pharma Friday – July 17, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community On July 14, Insulet Corporation announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, […]The post
    July 17, 2026
    Pharma Friday – July 10, 2026

    Pharma Friday – July 10, 2026

    Vertex to Acquire Crinetics Pharmaceuticals On July 6, Vertex Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc., a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash
    July 10, 2026
    Pharma Friday – June 26, 2026

    Pharma Friday – June 26, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Sanofi’s Tzield Approved in the U.S. for Patients with Stage 3 Type 1 DiabetesOn June 13, Sanofi announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in endogenous (own) insulin production in children aged eight
    June 26, 2026
    Pharma Friday – ENDO 2026 Edition – June 19, 2026

    Pharma Friday – ENDO 2026 Edition – June 19, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in CAH at ENDO 2026On June 14, Crinetics Pharmaceuticals, Inc.  presented data from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic
    June 19, 2026
    Pharma Friday – June 5, 2026

    Pharma Friday – June 5, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent TrialOn May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versu
    June 5, 2026
    Pharma Friday – May 22, 2026

    Pharma Friday – May 22, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Lilly’s Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity TrialOn May 21, Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of re
    May 22, 2026
    Pharma Friday – May 15, 2026

    Pharma Friday – May 15, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing SolutionOn May 13, Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) fo
    May 15, 2026
    Pharma Friday – May 8, 2026

    Pharma Friday – May 8, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Viridian Therapeutics Sees Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye DiseaseOn May 5, Viridian Therapeutics, Inc., announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disea
    May 8, 2026
    Pharma Friday – May 1, 2026

    Pharma Friday – May 1, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Shows Promise in Phase 3 TrialOn April 28, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy and
    May 1, 2026
    Pharma Friday – April 24, 2026

    Pharma Friday – April 24, 2026

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young ChildrenThe U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one
    April 24, 2026
    Contact
    1 (888) 363-6762
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.